Stanford Researchers Announce Immune Problems With Embryonic Stem Cells
Researchers at Stanford University have once again confirmed problems with immune rejection that are inherent in embryonic stem cells.
August 22, 2008
Researchers at Stanford University have once again confirmed problems with immune rejection that are inherent in embryonic stem cells.
Two major biotech companies in the stem cell industry sign yet another licensing agreement.
The biotech company Medistem demonstrates the therapeutic value of allogeneic endometrial regenerative cells in the treatment of critical limb ischemia.
The Harvard Stem Cell Institute announces the creation of 20 new, non-stem cell, cell lines which target specific diseases.
The biotech company Pluristem Therapeutics has developed an adult stem cell product for the prevention of clinical symptoms of multiple sclerosis.
Adult stem cells derived from bone marrow are used to treat restenosis in an animal model.